Rezenopy (naloxone) – New drug approval
April 19, 2024 - The FDA approved Summit Biosciences’ Rezenopy (naloxone) nasal spray, for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients.